Antimicrobial resistance in bacteria

[1] Cohen M.L., Changing patterns of infectious disease, Nature, 2000, 406, 762–767 http://dx.doi.org/10.1038/3502120610.1038/35021206Search in Google Scholar PubMed

[2] Yoneyama H., Katsumata R., Antibiotic resistance in bacteria and its future for novel antibiotic development, Biosci. Biotechnol. Biochem., 2006, 70, 1060–1075 http://dx.doi.org/10.1271/bbb.70.106010.1271/bbb.70.1060Search in Google Scholar PubMed

[3] Wright G.D., Bacterial resistance to antibiotics: enzymatic degradation and modification, Adv. Drug Deliv. Rev., 2005, 57, 1451–1470 http://dx.doi.org/10.1016/j.addr.2005.04.00210.1016/j.addr.2005.04.002Search in Google Scholar PubMed

[4] Rachakonda S., Cartee L., Challenges in antimicrobial drug discovery and the potential of nucleoside antibiotics, Curr. Med. Chem., 2004, 11, 775–793 http://dx.doi.org/10.2174/092986704345577410.2174/0929867043455774Search in Google Scholar PubMed

[5] Silver L.L., Novel inhibitors of bacterial cell wall synthesis, Curr. Opin. Microbiol., 2003, 6, 431–438 http://dx.doi.org/10.1016/j.mib.2003.08.00410.1016/j.mib.2003.08.004Search in Google Scholar PubMed

[6] Wise R., A review of the mechanisms of action and resistance of antimicrobial agents, Can. Respir. J., 1999, 6Suppl A, 20A–22A Search in Google Scholar

[7] Langton K.P., Henderson P.J., Herbert R.B., Antibiotic resistance: multidrug efflux proteins, a common transport mechanism?, Nat. Prod. Rep., 2005, 22, 439–451 http://dx.doi.org/10.1039/b413734p10.1039/b413734pSearch in Google Scholar PubMed

[8] Lambert P.A., Bacterial resistance to antibiotics: modified target sites, Adv. Drug Deliv. Rev., 2005, 57, 1471–1485 http://dx.doi.org/10.1016/j.addr.2005.04.00310.1016/j.addr.2005.04.003Search in Google Scholar PubMed

[9] Kahne D., Leimkuhler C., Lu W., Walsh C., Glycopeptide and lipoglycopeptide antibiotics, Chem. Rev., 2005, 105, 425–448 http://dx.doi.org/10.1021/cr030103a10.1021/cr030103aSearch in Google Scholar PubMed

[10] Reynolds P.E., Structure, biochemistry and mechanism of action of glycopeptide antibiotics, Eur. J. Clin. Microbiol. Infect. Dis., 1989, 8, 943–950 http://dx.doi.org/10.1007/BF0196756310.1007/BF01967563Search in Google Scholar PubMed

[11] Wilke M.S., Lovering A.L., Strynadka N.C., Betalactam antibiotic resistance: a current structural perspective, Curr. Opin. Microbiol., 2005, 8, 525–533 http://dx.doi.org/10.1016/j.mib.2005.08.01610.1016/j.mib.2005.08.016Search in Google Scholar PubMed

[12] Poole K., Resistance to beta-lactam antibiotics, Cell Mol. Life Sci., 2004, 61, 2200–2223 http://dx.doi.org/10.1007/s00018-004-4060-910.1007/s00018-004-4060-9Search in Google Scholar

[13] Fisher J.F., Meroueh S.O., Mobashery S., Bacterial resistance to beta-lactam antibiotics: compelling opportunism, compelling opportunity, Chem. Rev., 2005, 105, 395–424 http://dx.doi.org/10.1021/cr030102i10.1021/cr030102iSearch in Google Scholar

[14] Van Bambeke F., Van Laethem Y., Courvalin P., Tulkens P.M., Glycopeptide antibiotics: from conventional molecules to new derivatives, Drugs, 2004, 64, 913–936 http://dx.doi.org/10.2165/00003495-200464090-0000110.2165/00003495-200464090-00001Search in Google Scholar

[15] Williams D.H., The glycopeptide story—how to kill the deadly ’superbugs’, Nat. Prod. Rep., 1996, 13, 469–477 http://dx.doi.org/10.1039/np996130046910.1039/NP9961300469Search in Google Scholar

[16] Sussmuth R.D., Vancomycin resistance: small molecule approaches targeting the bacterial cell wall biosynthesis, Chembiochem., 2002, 3, 295–298 http://dx.doi.org/10.1002/1439-7633(20020402)3:4<295::AID-CBIC295>3.0.CO;2-G10.1002/1439-7633(20020402)3:4<295::AID-CBIC295>3.0.CO;2-GSearch in Google Scholar

[17] Schmitz F.J., Higgins P.G., Mayer S., Fluit A.C., Dalhoff A., Activity of quinolones against Grampositive cocci: mechanisms of drug action and bacterial resistance, Eur. J. Clin. Microbiol. Infect. Dis., 2002, 21, 647–659 http://dx.doi.org/10.1007/s10096-002-0788-z10.1007/s10096-002-0788-zSearch in Google Scholar

[18] Hooper D.C., Mechanisms of action of antimicrobials: focus on fluoroquinolones, Clin. Infect. Dis., 2001, 32Suppl 1, S9–S15 http://dx.doi.org/10.1086/31937010.1086/319370Search in Google Scholar

[19] Higgins P.G., Fluit A.C., Schmitz F.J., Fluoroquinolones: structure and target sites, Curr. Drug Targets., 2003, 4, 181–190 http://dx.doi.org/10.2174/138945003334692010.2174/1389450033346920Search in Google Scholar

[20] Dougherty T.J., Beaulieu D., Barrett J.F., New quinolones and the impact on resistance, Drug Discov. Today, 2001, 6, 529–536 http://dx.doi.org/10.1016/S1359-6446(01)01760-310.1016/S1359-6446(01)01760-3Search in Google Scholar

[21] Woodford N., Biological counterstrike: antibiotic resistance mechanisms of Gram-positive cocci, Clin. Microbiol. Infect., 2005, 11Suppl 3, 2–21 http://dx.doi.org/10.1111/j.1469-0691.2005.01140.x10.1111/j.1469-0691.2005.01140.xSearch in Google Scholar

[22] Eliopoulos G.M., Quinolone resistance mechanisms in pneumococci, Clin. Infect. Dis., 2004, 38Suppl 4, S350–S356 10.1086/382709Search in Google Scholar

[23] Vannuffel P., Cocito C., Mechanism of action of streptogramins and macrolides, Drugs, 1996, 51Suppl 1, 20–30 http://dx.doi.org/10.2165/00003495-199600511-0000610.2165/00003495-199600511-00006Search in Google Scholar PubMed

[24] Johnston N.J., Mukhtar T.A., Wright G.D., Streptogramin antibiotics: mode of action and resistance, Curr. Drug Targets., 2002, 3, 335–344 http://dx.doi.org/10.2174/138945002334767810.2174/1389450023347678Search in Google Scholar PubMed

[25] Shahid M., Aminoglycosidic aminocyclitol antibiotics-A wonder, but toxic drugs: Developments and clinical implications, Anti-infect. Agents Med. Chem., 2007, 6, 107–117 10.2174/187152107780361643Search in Google Scholar

[26] Jana S., Deb J.K., Molecular understanding of aminoglycoside action and resistance, Appl. Microbiol. Biotechnol., 2006, 70, 140–150 http://dx.doi.org/10.1007/s00253-005-0279-010.1007/s00253-005-0279-0Search in Google Scholar PubMed

[27] Kotra L.P., Haddad J., Mobashery S., Aminoglycosides: perspectives on mechanisms of action and resistance and strategies to counter resistance, Antimicrob. Agents Chemother., 2000, 44, 3249–3256 http://dx.doi.org/10.1128/AAC.44.12.3249-3256.200010.1128/AAC.44.12.3249-3256.2000Search in Google Scholar PubMed PubMed Central

[28] Speer B.S., Shoemaker N.B., Salyers A.A., Bacterial resistance to tetracycline: mechanisms, transfer, and clinical significance, Clin. Microbiol. Rev., 1992, 5, 387–399 10.1128/CMR.5.4.387Search in Google Scholar PubMed PubMed Central

[29] Roberts M.C., Update on acquired tetracycline resistance genes, FEMS Microbiol. Lett., 2005, 245, 195–203 http://dx.doi.org/10.1016/j.femsle.2005.02.03410.1016/j.femsle.2005.02.034Search in Google Scholar PubMed

[30] Chopra I., Roberts M., Tetracycline antibiotics: mode of action, applications, molecular biology, and epidemiology of bacterial resistance, Microbiol. Mol. Biol. Rev., 2001, 65, 232–260 http://dx.doi.org/10.1128/MMBR.65.2.232-260.200110.1128/MMBR.65.2.232-260.2001Search in Google Scholar PubMed PubMed Central

[31] Maravic G., Macrolide resistance based on the Ermmediated rRNA methylation, Curr. Drug Targets. Infect. Disord., 2004, 4, 193–202 http://dx.doi.org/10.2174/156800504334077710.2174/1568005043340777Search in Google Scholar PubMed

[32] Weisblum B., Erythromycin resistance by ribosome modification, Antimicrob. Agents Chemother., 1995, 39, 577–585 10.1128/AAC.39.3.577Search in Google Scholar PubMed PubMed Central

[33] Rezanka T., Spizek J., Sigler K., Medicinal use of lincosamides and microbial resistance to them, Anti-infect. Agents Med. Chem., 2007, 6, 133–144 10.2174/187152107780361670Search in Google Scholar

[34] Bozdogan B., Appelbaum P.C., Oxazolidinones: activity, mode of action, and mechanism of resistance, Int. J. Antimicrob. Agents, 2004, 23, 113–119 http://dx.doi.org/10.1016/j.ijantimicag.2003.11.00310.1016/j.ijantimicag.2003.11.003Search in Google Scholar PubMed

[35] Toh S.M., Xiong L., Arias C.A., Villegas M.V., Lolans K., Quinn J., Mankin A.S., Acquisition of a natural resistance gene renders a clinical strain of methicillin-resistant Staphylococcus aureus resistant to the synthetic antibiotic linezolid, Mol. Microbiol., 2007, 64, 1506–1514 http://dx.doi.org/10.1111/j.1365-2958.2007.05744.x10.1111/j.1365-2958.2007.05744.xSearch in Google Scholar PubMed PubMed Central

[36] Enoch D.A., Bygott J.M., Daly M.L., Karas J.A., Daptomycin, J. Infect., 2007, 55, 205–213 http://dx.doi.org/10.1016/j.jinf.2007.05.18010.1016/j.jinf.2007.05.180Search in Google Scholar PubMed

[37] Johnson A., Daptomycin in the treatment of skin, soft-tissue and invasive infections due to Gram-positive bacteria, Future. Microbiol., 2006, 1, 255–265 http://dx.doi.org/10.2217/17460913.1.3.25510.2217/17460913.1.3.255Search in Google Scholar PubMed

[38] Lange R.P., Locher H.H., Wyss P.C., Then R.L., The targets of currently used antibacterial agents: lessons for drug discovery, Curr. Pharm. Des, 2007, 13, 3140–3154 http://dx.doi.org/10.2174/13816120778211040810.2174/138161207782110408Search in Google Scholar PubMed